Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Corvus Pharmaceuticals Inc.
Headquarters: Burlingame, CA, United States of America
Website: http://www.corvuspharma.com
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Richard A. Miller, MD
Number Of Employees: 31
Enterprise Value: $275,428,633
PE Ratio: -3.04
Exchange/Ticker 1: NASDAQ:CRVS
Exchange/Ticker 2: N/A
Latest Market Cap: $200,319,312
BioCentury | Feb 8, 2024
Management Tracks
New chair, CFO for I-Mab as part of U.S. push
Plus: Artios hires Silverstein as CFO and updates from Astellas, atai, Cartography, Corvus and Helio
BioCentury | Jul 28, 2022
Management Tracks
Liz Bhatt becomes COO at Septerna
Plus new CBO, chief HR officer and head of regulatory at Prime, and SVP hires at CBM
BioCentury | Sep 17, 2021
Product Development
Questions about big benefit seen at ESMO with AZ’s CD73, NKG2A mAbs
Combos outperform active control in NSCLC, but control flops versus past studies
BioCentury | Jan 16, 2021
Product Development
Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte
As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs
BioCentury | Jun 7, 2019
Emerging Company Profile
insitro: machine learning with designated data
How insitro aims to improve machine learning-based target discovery by creating its own ‘fit-for-purpose’ data
BioCentury | Nov 17, 2018
Product Development
Betting Combos on Biomarkers
Pharmacodynamic biomarkers are driving IO combos in absence of monotherapy responses
BioCentury | Mar 24, 2018
Product Development
Optimism for A2A
Why two negative readouts haven't dimmed hope for A2A in cancer
Items per page:
1 - 10 of 31